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Abstract 
Small Molecule Sigma1 Modulators Induce the Degradation of Androgen Receptor 
and Splice Variants in Castration Resistant Prostate Cancer Cells 
Nan Chen 
Thesis advisor: Felix Kim 
Androgen receptor (AR) signaling is the primary driver for prostate cancer progression. 
Androgen deprivation therapy (ADT) although initially effective, will eventually fail with 
the development of castration resistant prostate cancer (CRPC), which is reflected by a 
restoration of AR activity. One way that patients develop CRPC is through constitutively 
active AR splice variants (ARVs). Theses ARVs can promote AR activity independent of 
androgen and are non-responsive to current AR axis inhibitors due to the lack of the 
ligand binding domain (LBD).  
Sigma1 is a unique ligand-operated scaffolding protein. It is highly expressed in cancer 
cells including prostate cancer cells, and plays an important role in cancer cell protein 
homeostasis including protein translation, folding, transport, and degradation. Our 
previous studies have shown that a small molecule Sigma1 modulator induces the 
degradation of full-length AR, suppresses its transcriptional activity and prevents the 
DHT-induced AR nuclear translocation.  
In this study, we first confirmed that the Sigma1 modulator can also reduce ARVs in 
CRPC cell lines and further demonstrated that the Sigma1 modulator induced degradation 
of ARVs is mediated by the ubiquitin proteasome system. Next, we compared the protein 
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degradation profile mediated by the Sigma1 modulator with that of an inhibitor for 
HSP90, a well-defined AR chaperone protein. It was found that the Sigma1 modulator 
and HSP90 inhibitor engage with some overlapping but also distinct client proteins, 
indicating the differences in mechanisms governing the actions of HSP90 and Sigma1. 
Finally, we combined docetaxel, a standard treatment for CRPC patients, with a drug-like 
version of the Sigma1 modulator to synergistically suppress CRPC cell colony formation 
using the Chou-Talalay method to assess the drug combination effect.  
Collectively, this study shows that the Sigma1 modulator can induce the degradations of 
AR and ARVs in CRPC cell lines and will support the development of potential novel 
therapeutics to counter the resistance to current AR signaling inhibitors mediated by 
ARVs.  
 
 
1 
Introduction 
Androgen receptor signaling activity is the primary driver of prostate cancer 
progression. Prostate cancer is one of the leading causes for cancer death in American 
men, with more than 26,000 men estimated to die from this disease in 2016 [1]. 
Metastatic prostate cancer  patients, although initially respond to the first line therapy, 
androgen deprivation therapy (ADT),  will uniformly enter into a lethal state of this 
disease, termed as metastatic castration resistant prostate cancer (mCRPC) [2].  
Androgen receptor (AR) signaling activity is the primary driver of prostate cancer 
progression. When the testosterone enters into prostate cancer cells, it will be 
intracellularly converted by the enzyme 5α-reductase into a more potent androgen 
receptor ligand, dihydrotestosterone (DHT), which can activate the cytoplasmic androgen 
receptor to translocate into the nucleus to initiate transcriptional activity of AR targeted 
genes that can promote prostate cancer cell growth and proliferation [3]. Therefore, 
current therapeutics are developed around the strategy to suppress AR signaling activity 
to inhibit tumor growth. Androgen deprivation therapy, which aims to lower the body 
level of androgen by chemical and physical castration, is the first line therapy for 
advanced prostate cancer. The AR signaling activity and disease burden will be initially 
suppressed by ADT due to the decreasing level of body androgen, however, after a few 
years, tumor adapts to the low body androgen environment and become castration-
resistant, reflected by a reactivated AR signaling activity [3, 4]. The mechanisms of 
castration resistance include the AR overexpress, gain-of-function mutation of AR, 
increasing intratumoral androgen synthesis and compensatory activation of multiple 
kinase pathways that can also promote the tumor growth [3].  
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Owing to the important role of AR axis activity in CRPC patients even under a low body 
androgen environment, current therapeutics are developed to further suppress this 
signaling activity by directly blocking the androgen and AR interaction or by inhibiting 
the increasing intratumoral androgen synthesis. Abiraterone and enzalutamide are the 
next generation of AR axis targeted therapies approved for the treatment of CRPC 
patients [2].  Enzalutamide is a potent AR antagonist, which binds to AR, preventing the 
DHT binding and AR nuclear translocation. Abiraterone is an inhibitor for CYP17A1, a 
key enzyme mediating systemic and intratumoral androgen synthesis [3], used to 
abrogate ligand supply for prostate cancer cells. However, those therapeutics cannot be 
curative for CRPC patients and a further resistance to those drugs develops, uniformly 
[5].  
ARVs confer the resistance to current AR targeted therapeutics for CRPC patients. 
One explanation for the failure of current AR targeted therapies is that they all ultimately 
target the ligand binding domain (LBD) of the androgen receptor. However, there are 
androgen receptor splice variants present in some CRPC patients which lack the LBD and 
cannot be touched by those AR targeted drugs.  The functional ARVs can be 
constitutively active to translocate into the nucleus independent of androgen binding, and 
activate the following transcription profile to promote the tumor growth. Because current 
AR targeted therapeutic agents are not effective in targeting ARVs, those splice variants 
can mediate resistance to them including enzalutamide and abiraterone [5-7].  
In addition to the next generation of AR axis targeted therapies, chemotherapy, such as 
Docetaxel, is also a standard treatment for CRPC patients [3]. A proposed mechanism of 
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action of docetaxel is that AR associates with microtubule to translocate into nucleus, so 
the microtubule stabilizer, docetaxel, can compromise the microtubule trafficking 
function and thus inhibit AR nuclear accumulation and signaling activity [8]. However, 
recent studies reveal that a specific form of splice variants, ARV7, does not associated 
with the microtubules and its nuclear translocation and transcriptional activity cannot be 
affected by the treatment with docetaxel [9], further indicating the critical role of splice 
variants in mediating broad resistance to current therapeutics for CRPC patients.  
In addition to developing therapeutics directly targeting AR, there is an interest in 
targeting and compromising the function of AR chaperone protein to indirectly alter AR 
signaling activity. HSP90 is a well-defined chaperone protein for androgen receptor [3, 
10]. It stabilizes and helps the AR protein to be well-folded in the cytoplasm. Some 
HSP90 inhibitors such as the gledanmycin analogs (e.g., 17-AAG) can destabilize the AR 
protein and thus suppress the AR activity [11]. However, 17-AAG failed to suppress the 
activity of functional ARVs [12, 13]. It was reported that HSP90 can associate with wide 
type AR but not ARVs and ARVs can function independent of HSP90, therefore ARVs is 
not responsive to 17-AAG treatment [12].  
Sigma1’s role in prostate cancer. Sigma1 is a unique 26 kilodalton, endoplasmic 
reticulum (ER) intergrated protein which lacks homology of any known mammalian 
protein without intrinsic enzymatic or signaling pathways identified currently [14, 15]. 
Initially discovered as an opioid receptor in animal studies, emerging evidences now 
consider Sigma1 as a chaperone protein regulating cell survival [16, 17]. It is an ligand 
operated protein (Figure 1) [18], and small molecule Sigma1 inhibitors suppress cell 
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survival in various cancer cell lines [19-21]. Recent studies in our lab found that small 
molecule Sigma1 inhibitors induce ER stress and activate the unfolded protein response 
(UPR) in a dose- and time-responsive manner. Sustained treatment of Sigma1 inhibitors 
leads to cancer cell death [22]. We hypothesize that Sigma1 is a ligand-operated 
scaffolding protein that helps cancer cells to handle with proteotoxic stress due to the 
high demand of protein production and quality control. Small molecule Sigma1 inhibitor 
can compromise Sigma1 function and thus disrupt the proteostasis in cancer cells.  
 
Figure 1. Sigma1 crystal structure. (A) Ribbon diagram showing 3 protomers forming 
a triangular structure with a single trans-membrane domain. (B) Cross-section view of the 
receptor showing the ligand binding site in yellow. (Derived from Schmidt et al, Nature 
2016.) 
In the context of prostate cancer, it was found that the AR gene expression profile is 
highly correlated with UPR gene profile, and the inhibition of IRE1α, a cytoprotective 
branch of UPR would result in prostate cancer cell death and tumor growth suppression 
in prostate cancer xenografts [23]. Some Sigma1 small molecule ligands can inhibit 
prostate cancer cell proliferation in vitro and tumor growth in vivo [21]. Based on 
A B 
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Sigma1’s potential role as a scaffolding protein (the central thesis in our lab), in this 
thesis project, we will ask if Sigma1 can scaffold the AR to regulate its stability and 
signaling activity, which is crucial for prostate cancer progression. 
In our study, we employed several clinically relevant prostate cancer cell lines to study 
Sigma1’s role in prostate cancer. LNCaP is derived from lymph node metastasis and 
harbors a AR mutation (T877A) which renders AR more promiscuous to promote cell 
growth and proliferation [24]. C4-2 is a CRPC model cell line derived from LNCaP [25]. 
22Rv1 and VCaP cell lines are model CRPC lines which not only express full length AR 
but also AR splice variants, and thus are androgen independent and non-responsive to AR 
targeted therapies [26, 27]. 
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Previous Study  
Sigma1 is required for prostate cancer cell survival. First, studies in the Kim lab 
confirmed that Sigma1 is required for prostate cancer growth and proliferation using the 
Sigma1 knockdown approach and small molecule Sigma1 modulator. We found that 
Sigma1 knockdown suppress the colony formations of C4-2 cells (Figure, 2A, B). Also, 
using a prototypic, selective small molecule inhibitor of Sigma1, IPAG (1-(4-
Iodophenyl)-3-(2-adamantyl)guanidine) [28], the prostate cancer cell viability and 
clonogenic growth in soft agar can be suppressed in a dose dependent manner (Figure 2C, 
D).  
 
Figure 2. Sigma1 is required for prostate cancer cell survival. (A) Sigma1 knockdown 
was confirmed in the C4-2 cells in the immunoblot. (B) Colony formation of C4-2 cells 
transfected with control siRNA and Sigma1 siRNA. (C) The quantification of alamar 
blue assay measuring the dose-dependent cell viability suppression of LNCaP, C4-2 and 
22Rv1 cells under the IPAG treatment. (D) Soft agar assay quantifying the relative 
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LNCaP, C4-2 and 22Rv1 cell colony formations in soft agar in response to the IPAG 
treatment.   
Sigma1 inhibitor suppresses AR activity and decreases full length AR through the 
ubiquitin proteasome pathway. Based on the potential role of the Sigma1 as a scaffold 
protein to promote cancer cell survival, we next investigated if Sigma1 ligands can act on 
the androgen receptor, the driver of prostate cancer cell growth. We measure the 
transcriptional levels of two well-known AR target genes KLK3/PSA and TMPRSS2 as 
the indicators for AR transcriptional activity. The prostate-specific antigen (PSA) is the 
best characterized AR target gene, which serves as a biomarker in clinic to monitor the 
prostate cancer progression [3]. TMPRSS2 is androgen regulated promoter and can fuse 
with Ets family members to form oncogenic chromosomal aberrations, which are 
associated with the early onset of prostate cancer and disease aggressiveness [29-31]. We 
found that IPAG can decently suppress the those AR target gene transcriptional levels in 
LNCaP cells (Figure 3A) [3]. Later, we examined the AR proteins levels in various 
prostate cancer cell lines. In addition to LNCaP, C4-2, we also tested if IPAG can 
decrease AR protein levels in LAPC-4 prostate cancer cell, which express wide type AR. 
All three cell lines have shown a robust decrease of AR protein levels in response to 
IPAG treatment (Figure 3B). Next, we investigated how IPAG reduced AR protein 
levels. Once the new AR protein synthesis was arrested by cycloheximde (CHX), IPAG 
treatment can speed up the gradual degradation of AR (Figure 3C). This indicates that the 
stability of AR was decreased in response to IPAG treatment. We also found that this 
induced degradation of AR was mediated by proteasome pathway but not autophagy 
(Figure 3D), since the proteasome inhibitor, MG132, but not autophagy inhibitor, BafA1, 
can rescue the IPAG-mediated AR degradation.  
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In my thesis, we hypothesized that Sigma1 may scaffold and stabilize both AR and ARVs 
in CRPC cell lines. I will further investigated whether IPAG can affect the ARVs in 
CRPC cell lines and compare Sigma1 inhibitor with HSP90 inhibitor, to investigate the 
potential mechanism of action governing Sigma1 function. Lastly, I will assess the effect 
of docetaxel, a standard treatment for CRPC patients, combined with a more drug-like 
Sigma1 inhibitor in suppressing CRPC cell colony formations. 
 
Figure 3. Sigma1 inhibitor suppresses the AR activity and induces the degradation 
of the androgen receptor through the ubiquitin proteasome pathway. (A) 
Quantitative reverse transcriptase PCR (qRT-PCR) measuring the transcription levels of 
AR target genes KLK3/PSA and TMPRSS2 in response to 16 hour 10µM IPAG 
treatment. (B) Immunoblots showing the AR levels in LAPC4, LNCaP and C4-2 cells 
under 16 hour treatment of 10µM IPAG. (C) LNCaP cell AR protein levels under control 
and 10µM IPAG treatments at indicated time points after the new protein synthesis was 
inhibited by cycloheximide. Remaining AR levels were quantified by densitometry data 
and normalized to the AR levels with no CHX treatment (0 hour treatment). (D) LNCaP 
cell AR protein levels under 16 hour co-treatment of 10 µM IPAG and 1 µM MG132, a 
proteasome inhibitor or 10µM IPAG and 100nM Bafilomycin A1 (BafA1), an autophagy 
inhibitor. Protein bands of each experimental conditions were quantified by densitometry 
and normalized to the control. Bar graphs present mean ± S.E.M from three independent 
experiments. *p < 0.05; **p < 0.01. 
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Material and Methods 
Chemical  
IPAG (1-(4-Iodophenyl)-3-(2-adamantyl) guanidine) was purchased from Tocris. 17-AAG 
(17-N-allylamino-17-demethoxygeldanamycin), MG132 (Z-Leu-Leu-Leu-al), and 5α-
dihydrotestosterone (DHT) were purchased from Sigma-Aldrich.  
CT-110 was synthesized in house by combining portions of the two known Sigma1 ligands, 
IPAG and haloperidol. The structure of CT-110 is confidential currently.  
Cell lines and cell culture  
The LNCaP, 22Rv1 and VCaP cell lines were purchased from ATCC. The LNCaP cells 
were maintained in RPMI 1640 medium supplemented with 5% fetal bovine serum 
(Lonza). 22Rv1 and VCaP cells were maintained in Improved MEM (Richter's Mod) 
medium (Corning) supplemented with 5% charcoal stripped serum (Lonza) before the 
DHT induction.  
Immunoblots and antibodies  
Cells were seeded 24 hours before the drug treatment to achieve stable, steady-state 
growth condition. After indicated drug treatment time, cells were harvested and lysed 
with in radioimmunoprecipitation assay buffer (Pierce) containing 10% glycerol (v/v), 
complete protease inhibitor cocktail (Pierce), and Halt phosphatase inhibitor cocktail 
(Pierce). Approximately 10–20 µg of protein was resolved on precast NOVEX 
polyacrylamide Tris-glycine gels (Invitrogen) and transferred on a Polyvinylidene 
Difluoride membrane.  The membrane was washed in a 20 mM Trisbuffered 137 mM 
saline solution (pH 7.6) containing 0.1% Tween-20 (polyoxyethylene (20) sorbitan 
10 
 
 
 
monolaurate) and the immunoblot was performed in that buffer containing 5% (w/v) 
blottinggrade nonfat dry milk (Bio-Rad) supplemented with respective antibodies. The 
Luminata Western HRP Substrate chemiluminescence kit (Millipore) was used to reveal 
immunoblotted proteins. The protein bands were quantified by densitometry using 
ImageJ. 
The primary antibody against androgen receptor (AR), HSP90, HSP70, HSP27, ErbB2/ 
HER2, ErbB3/ /HER3, Akt and glucocorticoid receptor (GR), and the secondary anti-
rabbit and anti-mouse antibody were all purchased from Cell Signaling Technologies 
(CST). The β-actin antibody was purchased from Santa Cruz Biotechnology. The Sigma1 
rabbit antibody was generated in house as described in somewhere else [20].  Anti-
Androgen Receptor (AR-V7 specific) antibody was purchased from Abcam.  
Colony formation assay  
2,200 22Rv1 cells were seeded in each well of tissue culture treated 12-well plates and 
maintained in 5% charcoal stripped serum (CSS) medium. After 24-hour incubation, the 
fresh medium containing drugs was applied in each well with indicated doses. Drug 
medium was replaced weekly until visible colonies in the untreated group could be seen 
and the total incubation time for 22Rv1 cells was around 3 weeks. After colonies were 
formed, they were washed by PBS and fixed by 4% formaldehyde. Subsequently, 
colonies were stained by 0.01% crystal violet (Fisher) and background was washed by 
water. After the plates were air dried, high quality pictures were taken for the colonies. 
The colony numbers were manually counted in the selected half portion of each well 
which has minimal edge effect affected.  
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Drug combination analysis  
Chou-Talalay method was performed to analyze the synergism of drug combinations [32, 
33]. Briefly, the Chou-Talalay method assigned each drug with a median effect plot 
based on median effect equation which is derived from the mass-action law. By using the 
equation and plot, the drug’s effect can be determined by a certain dose, and vice versa. 
The effect of drug combination was assessed by the combination index (CI), which is 
calculated as: CI = (D1)/(Dx1) + (D2)/(Dx2), where (D1) and (D2) are concentrations of 
Drug 1 and Drug 2, respectively, which result in certain effect x in combination (in the 
colony formation assay, x represents the relative decrease of colony formations), while 
(Dx1) and (Dx2) are the doses of Drug 1 and Drug 2, which result in the same effect x 
when used alone. The combinational effect is defined as synergy when the combination 
index is less than 1, additivity when the combination index equals 1 and antagonism 
when combination index is larger than 1. This equation is based on the assumption that 
the drugs in combination are mutually exclusive (have the same mode of action). If the 
drugs in combination are mutually non-exclusive, the previous CI equation should 
include a third term [(D1)(D2)]/[(Dx1)(Dx2)] [32]. Therefore, the modified CI value will 
be higher and more conservative [33]. We analyze the drug combinational effect of CT-
110 and docetaxel with the conservative assumption of mutually nonexclusively drug 
interactions. The median effect plot of each drug and CI values for drug combination 
were determined using the CompuSyn software with manual correction of CI value for 
mutually nonexclusively drug combination, which is not incorporated in the CompuSyn 
software [34]. Only the data points on the linear part of each drug dose response curve 
were selected to generate median effect curves and CI values in that software [35].  
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Statistical analysis  
Student’s t-test was performed to analyze the significance of difference between two 
groups. Specifically, in Chou-Talalay method, one group, two tailed t-test was performed 
to determine if the CI values generated from triplicates are significantly different from 
“1”, which presents the additivity. The comparisons among multiple groups was 
determined by the one-way ANOVA analysis followed by Bonferroni’s post-test using 
Prism software (GraphPad).  
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Results 
Selectivity of protein degradation mediated by Sigma1 inhibitor compared with HSP90 
inhibitor. Our previous study has shown that Sigma1 is required for prostate cancer cell 
survival and small molecule Sigma1 inhibitor induces the AR degradation and suppress 
the AR activity (Figure 2, 3). Recall that we hypothesize Sigma1 can scaffold AR to 
maintain its protein stability and to localize it to specific cellular area to function, it is 
worthwhile to bring up HSP90, a well-defined AR chaperone protein in the comparison 
with Sigma1 [36, 37]. The HSP90 inhibitor, 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG),  can compromise HSP90 function and thus lead to 
the proteasome degradation of HSP90 client proteins including AR [38], then we wanted 
to ask if the Sigma1 inhibitor, which also induces the AR degradation, share some 
mechanism of actions with HSP90 inhibitor. We tested those two inhibitors on a panel of 
HSP90 client proteins and found that they can mediate some overlapping but also distinct 
protein degradation profile (Figure 4A, B). Androgen receptor, ErbB2/HER2 and 
ErbB3/HER3, those HSP90 client proteins driving prostate cancer survival were all 
eliminated by IPAG and 17-AAG. However, the significant degradations of AKT and 
glucocorticoid receptor (GR) were only observed in HSP90 inhibition but not IPAG 
treatment. Given the similar signaling pathway of GR and AR, it is surprising that IPAG 
only affects AR, but it further highlights the selectivity of Sigma1 inhibition mediated 
protein degradation. Figure 4C and D indicate the distinct mechanism of actions of IPAG 
and 17-AAG. The induction levels of HSP70, HSP27 chaperone proteins are the marker 
of 17-AAG mediated HSP90 inhibition as a compensatory mechanism to rescue the 
misfolded proteins [10]. However, HSP70 and HSP27 protein levels barely changed in 
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response to IPAG treatment. Collectively, these data suggest that Sigma1 and HSP90 
have overlapping but also distinct protein engaged profile, and Sigma1 inhibitor has a 
different mechanism of action to induce protein degradation compared with HSP90 
inhibitor. 
 
Figure 4. Differential protein degradation mediated by Sigma1 inhibitor and HSP90 
inhibitor. (A-B) HSP90 client protein levels were examined in immunoblots with 
increasing concentrations of IPAG (3, 10 µM) and 17-AAG (0.3, 1 µM) under 16 hour 
drug treatments. The protein bands were quantified by densitometry and normalized to 
the control. Data present mean ± S.E.M from three independent experiments. (C-D) The 
hall markers of HSP90 inhibition were examined in immunoblots in response to 
increasing concentrations of IPAG (3, 10 µM) and 17-AAG (1, 3 µM) under 16 hour 
drug treatments.  
 
IPAG but not 17-AAG induces the degradations of both full length AR and splice 
variants. HSP90 can chaperone with full length AR but not AR splice variants which 
lack LBD domain to physically interact with HSP90 [12]. Therefore, it is interesting to 
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investigate whether the Sigma1 inhibitor, IPAG can affect the ARVs using 22Rv1 cell 
line which can express an abundance level of ARVs. Strikingly, both full length and 
splice variants of AR were eliminated by IPAG treatment, however, 17-AAG only 
affected the full length AR, leaving splice variants unaffected (Figure 5A, B). In addition, 
we took a closer look at a specific AR splice variant, ARV7, using a specific antibody 
developed for it. ARV7 expression is highly correlated with enzalutamide resistance and 
prostate cancer progression in clinic [5] and is also confirmed to be expressed in 22Rv1 
cells [39]. In Figure 5C and D, it shows IPAG can consistently decrease the ARV7 level 
while 17-AAG cannot. Next, we confirmed the effect of IPAG to induce the degradation 
of both AR and ARVs using the other CRPC cell line, VCaP, which also expresses high-
level ARVs (Figure 5E). These data suggest that IPAG is unique compared to 17-AAG in 
targeting ARVs and further highlight the distinct mechanism of actions of Sigma1 and 
HSP90 chaperone proteins.  
 
Figure 5. Sigma1 inhibitor but not HSP90 inhibitor induces the degradations of both 
AR and ARVs. (A-B) Both AR and ARVs protein levels in 22Rv1 cells were examined 
in immunoblots under 16 hour drug treatment of 10µM IPAG and 3µM 17-AAG. Bar 
graphs present mean ± S.E.M from three independent experiments. ***p < 0.001. (C-D) 
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A specific format of ARVs, ARV7 protein level in 22Rv1 cells was examined in 
immunoblots under 16 hour drug treatment of 10µM IPAG and 3 µM 17-AAG. ***p < 
0.001. (E) The AR, ARVs, and ARV7 protein levels were examined in VCaP cells by 
immunoblots following 16 hour drug treatment of 10 µM IPAG and 3 µM 17-AAG.  
 
IPAG induced ARV degradation is also mediated through ubiquitin proteasome 
pathway. Since the previous study showed that full length AR degradation is induced by 
IPAG through the proteasome pathway, next, we confirmed that this pathway also applies 
to the degradation of ARVs (Figure 6A, B). It was found that the proteasome inhibitor, 
MG132, rescued the IPAG induced AR and ARVs (includes ARV7, specifically) 
degradations, bringing them up to the control level.   
 
Figure 6. IPAG induced ARVs degradation is mediated through ubiquitin 
proteasome pathway. (A-B) AR, ARVs and ARv7 levels in 22Rv1 cells were examined 
in immunoblots under 8 hour drug treatment of 10µM IPAG, 2 µM MG132 alone or both 
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of them. Bar graphs present mean ± S.E.M from three independent experiments. *p < 
0.05; **p < 0.01; ***p < 0.001. 
 
IPAG suppresses AR and ARV transcriptional activity. We next wanted to confirm if the 
elimination of AR and ARV protein levels is corresponding with the AR signaling 
activity suppression under IPAG treatment. When 22Rv1 cells were cultured in charcoal 
stripped serum (CSS) medium where most full length AR cannot be activated due to the 
lack of androgen in the medium, we can still find a basal level of AR transcriptional 
activity (Figure 7A).  Since ARVs can also activate the transcription of canonical AR full 
length specifically regulated genes including KLK3/PSA and TMPRSS2 [40-42], the 
basal level of those gene transcriptions is probably contributed by the constitutively 
active AR splice variants under the CSS medium culturing condition. IPAG treatment can 
significantly lower this basal level, indicating that ARV transcriptional activity was 
suppressed. Even under the DHT induction, IPAG can bring AR transcriptional activity 
down to a level slightly below the control (Figure 7A).  
In contrast to IPAG, 17-AAG cannot alter the transcriptional activity of ARVs when 
22Rv1 was cultured in CSS medium (Figure 7B). 17-AAG can downregulate the AR 
activity only when full length AR is activated under DHT treatment (Figure 7B).  
These results indicate that Sigma1 inhibition can result in the suppressing of both AR and 
ARV activity, however, 17-AAG can only alter the AR activity but not ARV activity, 
which is consistent with the immunoblot results showing that both AR and ARV level 
can be reduced by IPAG but not 17-AAG (Figure 5).  
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Figure 7. IPAG suppresses AR and ARVs transcriptional activity. (A, B) 
Transcription levels of AR target genes KLK3/PSA and TMPRSS2 measured by qRT-
PCR under 16 hour treatment of 10 µM IPAG or 3 µM 17-AAG with or without 1 nM 
DHT induction. Bar graphs present mean ± S.E.M from three independent experiments. 
This figure was conducted by Jeff Thomas in the Kim Lab.  
 
The synergistic effect of CT-110 and docetaxel combination in suppressing 22Rv1 cell 
colony formations. Drug combination is an important approach in cancer therapy to 
achieve the potential synergistic effect, reduce the doses and toxic effects of a single drug 
and delay the drug resistance [35]. We already have found that IPAG is not a drug-like 
compound as it caused severe toxic effect in animal models in our lab. A more drug-like 
version of Sigma1 inhibitor, CT-110 was synthesized by combining portions of the two 
known Sigma1 ligands, IPAG and haloperidol and our animal models are well tolerated 
with this compound. First, we confirmed CT-110 can pharmacologically decrease both 
AR and ARV protein levels in 22Rv1 cells (Figure 8A). Therefore, it is worthwhile to 
combine this drug-like compound, CT-110 with the current standard treatment for CRPC 
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patients such as docetaxel. The Chou-Talalay method was used to analyze the drug 
combination effect based on the median effect plots of the drugs which are derived from 
the mass-action law, and it is widely and commonly used for synergy assessment [32, 
33]. It was found that 3 µM CT-110 synergistically enhanced 0.25 nM Docetaxel’s effect 
to inhibit 22Rv1 colony formations (Figure 8C, D).  
 
Figure 8. Synergistic effect of Sigma1 inhibitor and docetaxel combination in 
suppressing the 22Rv1 colony formations.  (A) Immunoblots confirming CT-110 can 
also pharmacologically reduce the AR and ARVs levels in 22Rv1 cells under 16 hour 
treatment of 10 and 20 µM CT-110. (B) Representative images of 22Rv1 colony 
formations under control, 3 µM CT-110, 0.25 nM docetaxel and the combination of 3 µM 
CT-110 and 0.25 nM docetaxel treatment. (C) Analysis of combinational effect of CT-
110 and docetaxel using a normalized isobologram from a particular replicate group. Y 
axis presents (DCT110)/(DxCT110) and X axis presents (DDoc)/(DxDoc), where (DCT110) and 
(DDoc) are concentrations of CT-110 and Docetaxel, respectively, when used in 
combination to result in certain x (in the colony formation assay, x represents the relative 
decrease of colony formations), while (DxCT-110) and (DxDoc) are the doses of those two 
drugs which result in the same effect x when used alone. Blue circle indicates 1 µM CT-
110 and 0.125 µM docetaxel combination. Red square indicates 3 µM CT-110 and 0.125 
µM docetaxel combination. Green triangle indicates 1 µM CT-110 and 0.25 µM 
docetaxel combination. Pink triangle indicates 3 µM CT-110 and 0.25 µM docetaxel 
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combination. The data points below the additive line indicate synergy. (D) Mean 
combination index values under indicated doses of CT-110 and docetaxel combinations. 
The combinational effect is defined as synergy when the combination index is 
significantly less than 1, additivity when the combination index is not significantly 
different from 1 and antagonism when combination index is significantly larger than 1. 
Error bars indicates the 95% confidence intervals of the mean values generated from 
technique triplicates.  
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Discussion 
The potential role of Sigma1 as a scaffold protein in the AR axis of prostate cancer 
cells. Sigma1 is a primarily ER-integrated protein without any intrinsic signaling or 
enzymatic activity identified [17]. Increasing evidence shows that it plays an important 
role in modulating many human physiological disorders including cardiovascular, 
nervous diseases and cancer [15]. However, the details about the molecular mechanism of 
Sigma1 function was still not clear, even the topology of Sigma1 was under debate until 
the recent publication reveals the crystal structure of human Sigma1 protein [18]. The 
Sigma1 has an oligomeric structure integrated in ER, with a flat C-terminal domain 
facing the cytosolic side (Figure 1). The illustration of Sigma1 topology and crystal 
structure is critical since those findings will facilitate the clarification of Sigma1 function 
and the mechanism of actions for Sigma1 modulators.  
Recent studies reported that Sigma1 can act as a chaperone protein to support functional 
protein transportation and modulate the inter-organelle signaling across cytoplasm, 
mitochondria and nucleus [16, 17]. Given the wide-spreading structure of ER within the 
cell, Sigma1 can function as a scaffold protein to help the client proteins to localize in a 
specific cellular area with supporting structure of ER [43].  
The AR axis in prostate cancer cells is an excellent example showing how localization of 
a protein affects its function. Upon the activation of ligand binding, cytoplasmic AR 
translocates into the nucleus to initiate transcriptional activity of targeted genes for cancer 
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cell survival. Therefore, we examined Sigma1 protein in this signaling context to 
investigate the physiological role of Sigma1. Our lab found that the Sigma1 modulator, 
IPAG, can prevent the translocation of AR into nucleus (data not shown). Instead of 
going to the nucleus to function, both full length and splice variants of AR end up in an 
ubiquitin proteasome-mediated degradation under IPAG treatment (Figure 6). 
Interestingly, Sigma1 appears to function differently from the well-defined AR 
chaperone, HSP90. The Sigma1 modulator IPAG, mediates an overlapping but also 
distinct protein degradation profile when compared to the HSP90 inhibitor 17-AAG 
(Figure 4A-B). IPAG cannot induce the compensatory increase of HSP70 and HSP27, the 
hallmarks for the HSP90 inhibition (Figure 4C-D). IPAG can induce the degradation of 
ARV, which cannot be touched by 17-AAG (Figure 5). Finally, our lab found that 
Sigma1 can physically associate with full length AR and two splice variants, ARV7 and 
ARv567 (data not shown), further suggesting Sigma1’s potential role in regulating the 
AR axis by scaffolding both full length and splice variants of AR.   
Targeting the ARV by small molecule Sigma1 modulators. Traditional drug 
development of AR signaling inhibitor focuses on targeting the ligand bind domain 
(LBD) of AR, trying to block the AR-ligand interaction, therefore inhibiting AR activity. 
However, AR splice variants which lack LBD, due to their constitutive activity 
independent of androgen binding, confer resistance to current AR targeted therapeutics. 
Furthermore, recent studies reported that a specific AR splice variant, ARV7, mediates 
the resistance to the treatment with taxanes, a standard therapy for CRPC patients, since it 
can translocate into nucleus and function independent of microtubules [9]. Therefore, 
developing therapeutics targeting AR splice variants is becoming crucial for addressing 
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the resistance to current treatments for CRPC patients. The functional ARVs harbor N-
terminal domain (NTD) and DNA-binding domain (DBD), however, it is hard to develop 
a small molecular drug targeting the NTD, which is intrinsically disordered [44]. There 
are also limited reports about developing therapeutics targeting DBD since it will raise 
concern of selectivity due to the homology of the DBD sequence among AR and other 
nuclear receptors [45]. Therefore, no drugs targeting AR NTD and DBD are currently 
under clinical use and only a small molecular AR N-terminal antagonist was developed 
recently and shown a decent efficacy to inhibit the AR and ARV activity and to inhibit 
tumor growth in xenografts [44]. In terms of our strategy to target the ARVs, we use a 
small molecule modulator to target Sigma1, which can physically with both AR and 
ARVs, to shift AR and ARVs into ubiquitin proteasome mediated degradation rather than 
translocating into the nucleus, therefore suppressing both AR and ARVs’ transcriptional 
activities and subsequent tumor growth (Figure 7, 9).   
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Figure 9. Targeting both AR and ARVs by Sigma1 modulators to suppress prostate 
cancer progression.  
 
However, the molecular mechanism of Sigma1 ligand’s action is still not clear. In fact, 
since there is no intrinsic signaling identified for Sigma1, the classification of the Sigma1 
ligands as agonist or antagonist is mainly based on the behavioral studies from animal 
models [46]. The ligands identified as “agonist” are those that can recapitulate the 
phenotypes such as hyperlocomotion under Sigma1 overexpression, while the 
“antagonists” are those that can recapitulate the phenotypes under Sigma1 knockdown or 
block the “agonist”-like responses [18, 46]. IPAG is a prototypic, selective small 
molecule Sigma1 inhibitor and its ligand binding affinity, efficacy to induce UPR and 
inhibit cancer cell survival were confirmed by previous studies [21, 22, 28]. IPAG can be 
used as a tool to investigate the Sigma1 function but has poor drug-like properties. By 
combining the portions of the two known Sigma1 ligands, IPAG and haloperidol, we 
synthesized a series of Sigma1 ligands with a high affinity for Sigma1 and a similar 
mechanism of action as IPAG but with improved drug-like properties. CT-110 is among 
those novel Sigma1 ligands and the was well tolerated in mice tested in house. The recent 
publication of Sigma1 crystal structure supports our central thesis regarding Sigma1 as a 
ligand-operated scaffolding protein and furthermore, it will facilitate our novel Sigma1 
compound development and optimization strategy. 
A concern about the selectivity of Sigma1 ligands may arise due to the wide expression 
of Sigma1 in tissues and the broad protein engagement profile associated with Sigma1. 
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However, it is noteworthy that Sigma1 is overexpressed in various cancer tissues [21]. 
Given the hypoxia and nutrition deprivation in tumor microenvironment and the massive 
protein production requirement for over-activated growth and metabolism, cancer cells 
are living in a much more stressful environment than normal cells. Since we hypothesized 
that Sigma1 is a scaffold protein that localizes many oncogenic proteins to function and 
previous studies already have shown Sigma1 inhibition leads to UPR induction [22] and 
cell death [21], the overexpression of Sigma1 observed in various cancer cell lines may 
be an adaptive response to their stressful living environment [47]. Thus, cancer cells, 
compared with normal cells, may be prone to Sigma1 modulator treatment, which can 
selectively result in a mass of protein and signaling processing in them.  
In addition, it is worthwhile to point out that Sigma1 modulator may serve as a multi-
target drug as Sigma1 interacts with many proteins crucial for cancer cell survival. We 
found that Sigma1 modulator not only suppresses AR level but also ErbB2/HER2 and 
ErbB3/HER3, which may contribute to AR reactivation in the CRPC and abiraterone 
resistant prostate cancer (Figure 4B) [48].  Given the diverse targets and complex 
mechanism involved in the cancer progression, multi-target drugs may be beneficial to 
delay the tumor relapse and drug resistance in cancer treatments [49].  
Drug combination considerations and future experimental designs.  Drug combination 
is an important approach for the treatment of lethal diseases such as cancer and AIDS 
since it may achieve a synergistic effect of combined therapeutics, delay the induction of 
the drug resistance and decrease the doses of toxic drugs compared to using them alone 
[35]. A drug-like version of Sigma1 modulator, CT-110 was combined with docetaxel, a 
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standard treatment for CRPC patients, to investigate whether there is a synergism 
between those two drug combination first in vitro. Note that the CI determination of this 
study was based on the assumption that CT-110 and docetaxel are mutually non-
exclusively (different modes of action). CT-110 induces the degradations of AR and 
ARVs and docetaxel inhibits AR nuclear transport by compromising microtubule 
function, therefore, those two drugs may, at least partially, suppress the AR signaling 
activity and colony formations through different mechanisms of action. However, the 
exact meaning of “mutually exclusive” and “mutually non-exclusive” drug interactions 
are still not clear [33]. In this study, ‘mutually non-exclusive” drug interaction was 
assumed since it would generate a higher and conservative CI value [33, 35, 50], and we 
found that 3 µM CT-110 can significantly potentiate 0.25 nM docetaxel’s effect to 
suppress 22Rv1 cell colony formations even under this conservative assumption.  
According to Chou’s method, the minimal dose-effect points for accurate combination 
analysis for Drug A and Drug B were 5 data points, which contains two data points for 
Drug A, two data points for Drug B and one data point for drug combination [35]. That 
prerequisite applies to my data set for CT-110 and docetaxel drug combination. The data 
points which are not located on the linear part of dose response curves were deleted when 
inputting the data to the CompuSyn software for accurate CI determinations [35]. 
It is important to note that CT110 concentrations we used in combination result either in 
modest effect (CT110 1uM), or strong effect (CT110 3uM) in suppressing 22Rv1 cell 
colony formations. In terms of the future experimental design, we will try the 
combinations of the CT110 and docetaxel under the concentrations around their IC50s, 
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which may give us a better synergistic effect and a much lower CI index [32]. Also, a 
constant combination ratio of those two drugs will be performed to generate the classic 
isobolograms in the future [35].  
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